
VulnCheck Launches Integration with ThreatQuotient, a Securonix Company, to Help Defenders Prioritize Remediation with Powerful Threat & Exploit Intelligence Solution
The combined solution integrates VulnCheck's API into ThreatQuotient's ThreatQ Platform, enabling security teams to prioritize vulnerability remediation with greater scale, speed and precision.
Share
According to VulnCheck research, threat actors now exploit over a quarter of vulnerabilities (28.3%) within a day of CVE disclosure, marking an unprecedented pace. The VulnCheck-ThreatQ integration helps ThreatQuotient customers address these vulnerabilities faster by delivering timely updates on known exploited vulnerabilities (KEVs), potential attack vectors, and threat actor activities. This powerful combination of exploit and threat intelligence provides an early warning system that helps security analysts stay ahead of attacks.
'The fight against vulnerability exploitation is no easy feat. Timely intelligence is the difference between quick and effective threat response and an organization's most vulnerable data falling into the hands of a cybercriminal,' said Anthony Bettini, CEO and Founder of VulnCheck. 'VulnCheck's CDF integration with the ThreatQ platform increases access to the comprehensive vulnerability intelligence security teams need to protect their organization from threats.'
VulnCheck delivers the most comprehensive, real-time exploit and vulnerability intelligence, including KEVs, proof-of-concept exploits and weaponization details, autonomously collected at the time of disclosure. Powered by a continuously updated intelligence feed sourced from nearly 500 unique channels and more than 400 million records across the entire CVE landscape, VulnCheck offers unparalleled visibility into active and emerging threats. Its community feed is designed for seamless integration into security workflows and products.
The integration provides the following feeds into the ThreatQ platform:
VulnCheck Exploits - ingests exploited vulnerability data from VulnCheck's exploits index.
VulnCheck Threat Actors - ingests vulnerability data associated with threat actors from VulnCheck's threat-actors index.
VulnCheck Vulnerabilities - ingests vulnerability data from VulnCheck's vulncheck-nvd2 index.
For more information about VulnCheck and its intelligence services, visit https://vulncheck.com/.
About VulnCheck
VulnCheck is the exploit intelligence company helping enterprises, government organizations, and cybersecurity vendors solve the vulnerability prioritization challenge. Trusted by some of the world's largest organizations responsible for protecting hundreds of millions of systems and people, VulnCheck helps organizations outpace adversaries by providing the most comprehensive, real-time vulnerability intelligence that is autonomously correlated with unique, proprietary exploit and threat intelligence. Follow the company on LinkedIn or X.
To learn more about VulnCheck, visit: https://vulncheck.com/.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Energy Transfer Announces Second Quarter 2025 Earnings Release and Earnings Call Timing
DALLAS, July 08, 2025--(BUSINESS WIRE)--Energy Transfer LP (NYSE: ET) today announced that it plans to release earnings for the second quarter of 2025 on Wednesday, August 6, 2025, after the market closes. The company will also conduct a conference call on Wednesday, August 6, 2025 at 3:30 p.m. Central Time/4:30 p.m. Eastern Time to discuss quarterly results and provide a company update. The conference call will be broadcast live via an internet webcast, which can be accessed on Energy Transfer's website at The call will also be available for replay on Energy Transfer's website for a limited time. Energy Transfer LP (NYSE: ET) owns and operates one of the largest and most diversified portfolios of energy assets in the United States, with approximately 140,000 miles of pipeline and associated energy infrastructure. Energy Transfer's strategic network spans 44 states with assets in all of the major U.S. production basins. Energy Transfer is a publicly traded limited partnership with core operations that include complementary natural gas midstream, intrastate and interstate transportation and storage assets; crude oil, natural gas liquids ("NGL") and refined product transportation and terminalling assets; and NGL fractionation. Energy Transfer also owns Lake Charles LNG Company, as well as the general partner interests, the incentive distribution rights and approximately 21% of the outstanding common units of Sunoco LP (NYSE: SUN), and the general partner interests and approximately 38% of the outstanding common units of USA Compression Partners, LP (NYSE: USAC). For more information, visit the Energy Transfer LP website at The information contained in this press release is available on our website at View source version on Contacts Investor Relations:Bill BaergBrent RatliffLyndsay Hannah214-981-0795 Media Relations:Vicki Granado214-840-5820


Business Wire
36 minutes ago
- Business Wire
Energy Transfer Announces Second Quarter 2025 Earnings Release and Earnings Call Timing
DALLAS--(BUSINESS WIRE)-- Energy Transfer LP (NYSE: ET) today announced that it plans to release earnings for the second quarter of 2025 on Wednesday, August 6, 2025, after the market closes. The company will also conduct a conference call on Wednesday, August 6, 2025 at 3:30 p.m. Central Time/4:30 p.m. Eastern Time to discuss quarterly results and provide a company update. The conference call will be broadcast live via an internet webcast, which can be accessed on Energy Transfer's website at The call will also be available for replay on Energy Transfer's website for a limited time. Energy Transfer LP (NYSE: ET) owns and operates one of the largest and most diversified portfolios of energy assets in the United States, with approximately 140,000 miles of pipeline and associated energy infrastructure. Energy Transfer's strategic network spans 44 states with assets in all of the major U.S. production basins. Energy Transfer is a publicly traded limited partnership with core operations that include complementary natural gas midstream, intrastate and interstate transportation and storage assets; crude oil, natural gas liquids ('NGL') and refined product transportation and terminalling assets; and NGL fractionation. Energy Transfer also owns Lake Charles LNG Company, as well as the general partner interests, the incentive distribution rights and approximately 21% of the outstanding common units of Sunoco LP (NYSE: SUN), and the general partner interests and approximately 38% of the outstanding common units of USA Compression Partners, LP (NYSE: USAC). For more information, visit the Energy Transfer LP website at The information contained in this press release is available on our website at
Yahoo
36 minutes ago
- Yahoo
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
BOSTON, July 08, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. (VRTX-WEB) View source version on Contacts Vertex Pharmaceuticals Incorporated Investor Relations: investorinfo@ Sign in to access your portfolio